1,239 results on '"Reinisch W."'
Search Results
2. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
3. OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study
4. P820 Targeting MM-SES-CD < 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn’s disease: A post-hoc analysis of SEAVUE
5. P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease
6. P225 Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib
7. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials
8. P006 Development of a Crohn's disease molecular activity score to identify region-specific chronically inflamed and non-inflamed processes
9. P1180 Smoking behaviour and changes after diagnosis in patients with Crohn's disease in a tertiary referral hospital: A retrospective explorative study
10. P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn's Disease (RELIEVE UCCD)
11. P040 Prediction of endoscopic features of disease from single-cell RNA sequencing data in sigmoid colon of patients with ulcerative colitis
12. Colitis ulcerosa
13. Durchfall
14. A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY
15. A116 OPTIMIZING CROHN’S DISEASE ENDOSCOPIC SCORING OPERATING CHARACTERISTICS TO ASSIST WITH THE ADVENT OF ARTIFICIAL INTELLIGENCE
16. Durchfall
17. Colitis ulcerosa
18. P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
19. DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)
20. P462 Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders
21. P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease
22. P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
23. P471 A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative Colitis
24. P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
25. P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
26. P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study
27. P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study
28. P239 Incidence of Long COVID and impact of medications on the risk of developing Long COVID in a nationwide cohort of Inflammatory Bowel Disease patients
29. P856 Associations of antibiotics, hormonal therapies, oral contraceptives, and long-term NSAIDs with Inflammatory Bowel Disease: results from the Prospective Urban Rural Epidemiology (PURE) study
30. P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
31. P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study
32. P785 A retrospective cohort study on vedolizumab trough levels in Crohn’s disease patients
33. P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis
34. Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española)
35. Segundo Consenso Europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática Parte 1: Definiciones y diagnóstico (versión española)
36. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
37. DOP071 Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM
38. DOP065 Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial
39. DOP040 Five-year colectomy data from the observational postmarketing ulcerative colitis study, a European registry for adults with ulcerative colitis treated with originator infliximab or conventional therapy
40. DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
41. OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study
42. OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM
43. Long‐term safety of adalimumab in clinical trials in adult patients with Crohnʼs disease or ulcerative colitis
44. Biologics, novel therapeutic alternatives in inflammatory bowel disease
45. Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases–A nationwide, retrospective study
46. Das Therapieansprechen auf systemische Kortikosteroide bei Patienten mit aktiver Colitis ulcerosa ist mit der Regeneration des Mikrobioms und erhöhter mikrobielle Butyratproduktion assoziiert
47. Postoperative Immunsupression zeigt keinen Einfluss auf das endoskopische Rezidiv nach Darmresektionen bei PatientInnen mit Morbus Crohn- Eine retrospektive multizentrische Datenauswertung
48. Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases–A nationwide, retrospective study
49. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
50. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.